KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Gains from Investment Securities (2017 - 2025)

Bionano Genomics' Gains from Investment Securities history spans 5 years, with the latest figure at -$300000.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 205.63% year-over-year to -$300000.0; the TTM value through Sep 2025 reached -$314000.0, down 2515.38%, while the annual FY2024 figure was -$14000.0, 129.79% down from the prior year.
  • Gains from Investment Securities for Q2 2025 was -$300000.0 at Bionano Genomics, down from -$14000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $284000.0 in Q2 2024 and bottomed at -$300000.0 in Q2 2025.
  • The 5-year median for Gains from Investment Securities is $57000.0 (2023), against an average of $24307.7.
  • The largest YoY upside for Gains from Investment Securities was 960.61% in 2024 against a maximum downside of 2940.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $66000.0 in 2021, then surged by 324.24% to $280000.0 in 2022, then tumbled by 95.36% to $13000.0 in 2023, then plummeted by 207.69% to -$14000.0 in 2024, then crashed by 2042.86% to -$300000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Gains from Investment Securities are -$300000.0 (Q2 2025), -$14000.0 (Q4 2024), and $284000.0 (Q2 2024).